Published in HPB (Oxford) on June 01, 2010
High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology (2012) 1.42
Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol (2015) 1.05
Laparoscopic liver resection: Current role and limitations. World J Gastrointest Oncol (2012) 1.01
The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines. Mol Cell Biochem (2014) 1.00
Laparoscopic liver resection: Experience based guidelines. World J Gastrointest Surg (2016) 0.96
Factors in perioperative care that determine blood loss in liver surgery. HPB (Oxford) (2012) 0.93
Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma. World J Gastroenterol (2011) 0.90
Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol (2014) 0.90
Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension. PLoS One (2014) 0.89
AHPBA/SSO/SSAT sponsored Consensus Conference on Multidisciplinary Treatment of Hepatocellular Carcinoma. HPB (Oxford) (2010) 0.89
Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) (2014) 0.89
Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci (2012) 0.88
Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol (2013) 0.85
Crosstalk between Long Noncoding RNAs and MicroRNAs in Health and Disease. Int J Mol Sci (2016) 0.85
Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. Int J Hepatol (2011) 0.82
Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol (2011) 0.82
Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci (2013) 0.80
Resection for hepatocellular carcinoma. J Clin Exp Hepatol (2014) 0.79
Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg (2014) 0.78
Morbidity of hepatic resection for intermediate and advanced hepatocellular carcinoma. Langenbecks Arch Surg (2015) 0.78
Netrin-1 induces epithelial-mesenchymal transition and promotes hepatocellular carcinoma invasiveness. Dig Dis Sci (2014) 0.78
Surgical treatment of hepatocellular cancer: expert consensus conference. HPB (Oxford) (2010) 0.75
Increasing survival of hepatocellular carcinoma patients in Scotland: a review of national cancer registry data. HPB (Oxford) (2012) 0.75
Liver transplantation for hepatocellular carcinoma in Ireland: Pre-operative alpha-fetoprotein predicts tumour recurrence in a 14-year single-centre national experience. World J Transplant (2016) 0.75
What's New in Transarterial Therapies for Hepatocellular Carcinoma? Gastrointest Cancer Res (2012) 0.75
Disparities in care for patients with curable hepatocellular carcinoma. HPB (Oxford) (2015) 0.75
Risk factors for pulmonary complications after hepatic resection: role of intraoperative hemodynamic instability and hepatic ischemia. BMC Anesthesiol (2017) 0.75
New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol (2017) 0.75
Management of hepatocellular carcinoma. Hepatology (2005) 27.42
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 17.03
Estimating the world cancer burden: Globocan 2000. Int J Cancer (2001) 16.92
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology (2008) 8.24
Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology (2001) 6.19
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology (2002) 5.71
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (1999) 5.70
A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg (2006) 5.65
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg (1999) 4.97
Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol (2006) 3.65
Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl (2003) 3.11
Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg (2005) 3.02
Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer (2007) 2.83
Prospective evaluation of Pringle maneuver in hepatectomy for liver tumors by a randomized study. Ann Surg (1997) 2.83
A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl (2005) 2.56
Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg (2007) 2.53
Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg (2008) 2.31
Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl (2002) 2.28
Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg (2004) 2.20
Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg (2002) 2.14
Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl (2003) 2.04
Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology (2005) 2.04
Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg (2003) 2.03
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl (2002) 2.03
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg (2003) 2.02
Significance of resection margin in hepatectomy for hepatocellular carcinoma: A critical reappraisal. Ann Surg (2000) 2.01
Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg (2003) 1.88
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl (2003) 1.86
Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology (2009) 1.86
Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology (1987) 1.78
Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72
Hepatocellular carcinoma: current surgical management. Gastroenterology (2004) 1.66
Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. J Exp Ther Oncol (2008) 1.59
Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J Nanobiotechnology (2008) 1.56
Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery (2005) 1.54
Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol (2005) 1.53
Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg (2005) 1.52
Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl (2004) 1.47
Laparoscopic liver resection: a systematic review. J Hepatobiliary Pancreat Surg (2009) 1.39
Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg (2009) 1.37
Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg (2003) 1.35
Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma. BMC Gastroenterol (2009) 1.31
Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut (2002) 1.29
Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer (2005) 1.26
Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant (2008) 1.26
Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann Surg Oncol (2008) 1.18
Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg (2006) 1.11
Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement? Liver Transpl (2007) 1.08
Surgical treatment of hepatocellular carcinoma. HPB (Oxford) (2005) 1.04
Role of the anti-sigma factor SpoIIAB in regulation of sigmaG during Bacillus subtilis sporulation. J Bacteriol (2004) 1.03
Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant (2006) 0.97
Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg (2003) 0.96
A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care (Engl) (2009) 0.93
Liver resection for hepatocellular carcinoma. Surg Oncol Clin N Am (2008) 0.91
Local ablative therapies in HCC: percutaneous ethanol injection and radiofrequency ablation. Dig Dis (2009) 0.89
Prognostic significance of the DNA-index in liver transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg (2009) 0.89
Treatment of HCC in patients awaiting liver transplantation. Am J Transplant (2007) 0.86
Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol (2007) 0.84
A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int (2009) 0.83
Liver transplantation for hepatocellular carcinoma: expanding special priority to include stage III disease. Arch Surg (2005) 0.82
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Bowel obstruction following appendectomy: what is the true incidence? Ann Surg (2009) 2.50
Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol (2014) 2.38
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36
Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg (2009) 2.27
Bile duct injuries associated with laparoscopic cholecystectomy: timing of repair and long-term outcomes. Arch Surg (2010) 2.26
Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology (2006) 2.25
The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg (2007) 2.23
Postoperative complications following surgery for rectal cancer. Ann Surg (2010) 2.23
Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation (2004) 2.13
Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin (2002) 2.07
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Ann Surg (2016) 2.05
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis. Proc Natl Acad Sci U S A (2010) 1.95
Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg (2007) 1.86
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg (2008) 1.85
A population-based study of pyogenic liver abscesses in the United States: incidence, mortality, and temporal trends. Am J Gastroenterol (2009) 1.84
Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg (2004) 1.77
A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.76
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol (2005) 1.73
Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol (2007) 1.71
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology (2012) 1.70
Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer (2006) 1.66
Management of primary liver sarcomas. Cancer (2007) 1.65
Caudate hepatectomy for cancer: a single institution experience with 150 patients. J Am Coll Surg (2005) 1.64
Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol (2006) 1.60
Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg (2005) 1.60
Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) (2010) 1.59
Cystic lesions of the pancreas: selection criteria for operative and nonoperative management in 209 patients. J Gastrointest Surg (2003) 1.56
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
Management of perforation after endoscopic retrograde cholangiopancreatography (ERCP): a population-based review. HPB (Oxford) (2006) 1.56
Predicting in-hospital mortality in patients undergoing complex gastrointestinal surgery: determining the optimal risk adjustment method. Arch Surg (2011) 1.54
Incorporation of a laser range scanner into image-guided liver surgery: surface acquisition, registration, and tracking. Med Phys (2003) 1.52
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg (2007) 1.52
Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. Arch Surg (2010) 1.52
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol (2005) 1.52
Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev (2010) 1.51
18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg (2007) 1.51
Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) (2013) 1.50
Concepts and preliminary data toward the realization of image-guided liver surgery. J Gastrointest Surg (2007) 1.50
Factors associated with early recurrence after resection for hepatocellular carcinoma and outcomes. J Am Coll Surg (2005) 1.50
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2009) 1.50
Robust surface registration using salient anatomical features for image-guided liver surgery: algorithm and validation. Med Phys (2008) 1.49
Papillary phenotype confers improved survival after resection of hilar cholangiocarcinoma. Ann Surg (2005) 1.49
Compensating for intraoperative soft-tissue deformations using incomplete surface data and finite elements. IEEE Trans Med Imaging (2005) 1.49
Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases. Ann Surg Oncol (2008) 1.48
Extrahepatic bile duct carcinoid tumors: malignant biliary obstruction with a good prognosis. J Am Coll Surg (2007) 1.46
Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys (2002) 1.44
En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report. Gynecol Oncol (2006) 1.44
ACS-NSQIP has the potential to create an HPB-NSQIP option. HPB (Oxford) (2009) 1.44
Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol (2009) 1.44
CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer (2006) 1.44
Dramatic innovations in modern surgical subspecialties. Can J Surg (2010) 1.40
Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg (2007) 1.39
Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.39
Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin (2002) 1.32
Fate of the remnant pancreas after resection of noninvasive intraductal papillary mucinous neoplasm. J Am Coll Surg (2007) 1.30
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford) (2010) 1.30
Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg (2007) 1.29
AHPBA/SSO/SSAT Consensus Conference on Resectable and Borderline Resectable Pancreatic Cancer: rationale and overview of the conference. Ann Surg Oncol (2009) 1.29
Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg (2011) 1.24
Disparate outcomes in patients with colorectal cancer: effect of race on long-term survival. Arch Surg (2002) 1.24
Polypoid lesions of the gallbladder: diagnosis and followup. J Am Coll Surg (2009) 1.24
Epidural blood patch at C2: diagnosis and treatment of spontaneous intracranial hypotension. AJNR Am J Neuroradiol (2005) 1.22
Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys (2002) 1.21
Wound protectors reduce surgical site infection: a meta-analysis of randomized controlled trials. Ann Surg (2012) 1.21
T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol (2009) 1.20
Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol (2008) 1.19
Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol (2012) 1.18
Colorectal liver metastases contract centripetally with a response to chemotherapy: a histomorphologic study. Cancer (2008) 1.18
Assessment of donor liver steatosis: pathologist or automated software? Hum Pathol (2004) 1.17
Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol (2006) 1.17
Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg (2012) 1.17
The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors. Surgery (2008) 1.16
Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? HPB (Oxford) (2010) 1.13
Utilization of thyroidectomy for benign disease in the United States: a 15-year population-based study. Am J Surg (2011) 1.13
Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res (2009) 1.12
The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg (2003) 1.12
Clinical and pathologic features of proximal biliary strictures masquerading as hilar cholangiocarcinoma. J Am Coll Surg (2005) 1.12
Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol (2009) 1.11
Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg (2006) 1.11
Patterns of recurrence after ablation of colorectal cancer liver metastases. Ann Surg Oncol (2011) 1.10